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ABSTRAK 
 
Penelitian sebelumya menunjukkan bahwa berberin, alkaloid yang terdapat pada beberapa 
tumbuhan seperti akar kuning (Arcangelisia flava) menunjukkan potensi inhibisi terhadap Human 
epidermal receptor-2 (HER2). Modifikasi pharmacophore pada struktur kimia berberin diprediksi 
dapat meningkatkan afinitas derivat berberin terhadap HER2. Tujuan penelitian ini adalah 
menemukan pharmacophore utama pada berberin yang memiliki pengaruh paling penting 
terhadap afinitas berberin pada HER2. 
Metode yang digunakan adalah molecular docking hasil modifikasi pharmacophore 
terhadap HER2. 
Hasil docking menunjukkan atom O pada posisi nomor 23 memiliki pengaruh penting 
terhadap afinitas berberin pada HER2, dimana modifikasi atom O menurunkan afinitas berberin. 
Afinitas tertinggi ditunjukkan oleh derivat berberin-6 dengan energi bebas ikatan dan konstanta 
disosiasi secara berturut-turut sebesar -10,80 kcal/mol dan 12,17 nM. Berbeda dengan derivat 
berberin lainnya, derivat berberin-6 tidak berinteraksi dengan asam amino treonin pada posisi 
862. Hal tersebut memberikan prediksi bahwa interaksi pada asam amino tersebut berpotensi 
menurunkan afinitas berberin terhadap sisi aktif HER2. Lebih jauh derivat berberin-6 dapat 
dikembangkan menjadi inhibitor HER2 dan berpotensi untuk dikembangkan pada terapi kanker 
payudara HER2-positif. 
 
Kata kunci: berberin, HER2, pharmacophore 
 
ABSTRACT 
 
Previous research has shown that berberine, an alkaloid found in several plants such as 
akar kuning (Arcangelisia flava) shows the potential for inhibition of Human epidermal receptor-2 
(HER2). Pharmacophore modification on the berberine was predicted could increase the affinity 
of berberine derivatives against HER2. The present study aims to determine the main 
pharmacophore of berberine with the highest influence towards berberine affinity against HER2. 
Molecular docking was performed on several modified pharmacophore of berberine against 
HER2. 
The docking results show that O atom at position number 23 has the most important 
influence on the berberine affinity towards HER2, where modification of O atom resulting in a 
decrease of berberine affinity. The highest affinity showed by derivate berberine-6 with the free 
energy of binding score and dissociation constant -10.80 kcal/mol and 12.17 nM, respectively. In 
contrast with other berberine derivatives, the berberine-6 derivate does not interact with the amino 
acid threonine at position 862. It provides a prediction that interaction of that amino acid potentially 
decrease the berberine activity towards active site of HER2. Further, derivate berberine-6 could 
be developed into HER2 inhibitor and should be potential to be developed as HER2-positive 
breast cancer therapy. 
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INTRODUCTION 
The anticancer properties of akar 
kuning (Arcangelisia flava) has been 
studied in various types of cancer cells, 
one of them in breast cancer (Sun et al., 
2009). The activity is due to various 
secondary metabolites of akar kuning, 
especially on the stem (Kunii et al., 
1985; Subiandono & Heriyanto, 2009). 
Our previous study showed that 
berberine, an alkaloid found in the stem 
part of akar kuning, has the highest 
affinity for HER2 receptor compared to 
other secondary metabolites (Pratama, 
2016). Inhibition of HER2 receptor itself 
is known to be one of the main 
therapeutic approaches to breast 
cancer, especially HER2-positive breast 
cancer (Incorvati et al., 2013). 
Despite has the highest affinity, 
berberine affinity is still lower than 
several known HER2 inhibitors including 
TAK-285, an investigational drug with 
potent HER2 inhibition properties 
(Pratama, 2016). Optimization of 
berberine affinity as HER2 inhibitor can 
be done with several ways, one of them 
by pharmacophore modification 
(Kaserer et al., 2015). The discovery of 
major pharmacophore with the greatest 
influence on the affinity of a ligand is 
performed by removing each 
pharmacophore from a ligand one by 
one (Kroemer, 2007). The modification 
result was reexamined by molecular 
docking method to see changes in the 
affinity of modified ligands (Meng et al., 
2011). 
This study aims to find the best-
modified pharmacophore results from 
berberine as HER2 inhibitor. The 
modification results were retested and 
compared with a known HER2 inhibitor 
to determine the potency of berberine 
derivatives in HER2-positive breast 
cancer therapy.
 
 
Figure 1. 2D structure of berberine 
 
MATERIALS AND METHODS 
The ligand used in this study were 
berberine and derivatives namely 
berberine-1 (O-19 to C-19), berberine-2 
(O-20 to C-20), berberine-3 (N-8 to C-8), 
berberine-4 (O-23 to C-23), and 
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berberine-5 (O-25 to C-25). Structures of 
berberine and derivatives were sketched 
using GaussView 3.08 software from 
Gaussian, Inc (Cosconati et al., 2010). 
The molecular structure of HER2 was 
obtained from the website of Protein 
Data Bank (PDB) www.rscb.org. HER2 
structure used in this study contains 
tyrosine kinase domain from HER2 in 
complexed with known HER2 inhibitor 
TAK-285 (PDB ID 3PP0) (Aertgeerts et 
al, 2011). Tyrosine kinase domain was 
chosen since this site have already 
known development for HER2 inhibitor 
development (Pratama, 2015). 
All ligand structures were 
geometry optimized by the molecular 
mechanic method with AMBER force 
field using Gaussian 03W software from 
Gaussian, Inc. Geometry optimization 
provided an ideal conformation of 
following ligands that approaching 
conformation of the compound in nature 
(Cosconati et al., 2010). The format of 
optimized structures changed from .log 
to .pdb using OpenBabel 2.3.2 software 
(O’Boyle et al., 2011). Molecular docking 
performed using AutoDock 4.2.6 
software from The Scripps Research 
Institute (Morris et al., 2009). 
Docking process validation was 
performed by redocking using TAK-285 
as the co-crystal ligand of HER2 in 3PP0 
receptor active site with pose selection 
method (Kontoyianni et al., 2004). The 
parameters of validation observed were 
root-mean-square deviation (RMSD) of 
co-crystal ligand at selected binding site. 
Docking process is preferred to predict 
results from experimental poses with 
RMSD score no more than 2Å. Smaller 
RMSD score indicates the closer 
position of the redocking result against 
crystallography result (Bissantz et al., 
2000). 
Molecular docking for all test 
ligands performed in same way as 
validation process using similar grid box 
size and position (Pratama, 2015). The 
main parameter observed were the free 
energy of binding (ΔG), the dissociation 
constant (Ki), amino acids residues, and 
numbers of hydrogen bonds. Ligand 
affinity to the receptor was determined 
by ΔG and Ki scores. More negative ΔG 
and lower Ki indicated higher ligand 
affinity toward receptor’s binding site 
(Kim & Skolnick, 2008). The ligand with 
amino acids residues and numbers of 
hydrogen bonds which closest to co-
crystal ligand indicate similarity type of 
interaction, in this case, describes 
similarity of activities (Cosconati et al., 
2010). 
 
RESULTS AND DISCUSSION 
Test ligands were sketched and 
performed geometry optimization with 
AMBER force field. All ligands structures 
were shown in Table 1.
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Table 1. 3D structure of ligands 
Compounds 2D structure 3D structure 
Berberine 
(BBR-0) 
 
 
Berberine-1 
(BBR-1) 
 
 
Berberine-2 
(BBR-2) 
 
 
Berberine-3 
(BBR-3) 
 
 
Berberine-4 
(BBR-4) 
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Berberine-5 
(BBR-5) 
 
 
 
Docking validation was done with 
redocking method using AutoDock 
4.2.6. Validation was performed on the 
entire binding site of TAK-285 as a co-
crystal ligand of the selected receptor 
(Cosconati et al., 2010). Redocking 
results from this study were provided 
almost at the stacked position with 
crystallography results (Figure 2) with 
RMSD value 0.807 Å, indicated that 
receptor 3PP0 was valid for molecular 
docking purpose (Bissantz et al., 2000). 
Other parameters observed in validation 
was ΔG, Ki, amino acids residues, and 
numbers of hydrogen bonds of the co-
crystal ligand as shown in Table 2. 
 
Figure 2. Results of validation from TAK-285; root-mean-square deviation = 0.807 Å (Red: TAK-
285 redocking results; blue: TAK-285 crystallography result) 
 
Table 2. Validation results of HER2 receptor PDB ID 3PP0 with TAK-285 
Receptor Ligand 
RMSD 
(Å) 
ΔG 
(kcal/mol) 
Ki, (µM) Amino acids residues 
Numbers of 
hydrogen 
bonds 
HER2 TAK-285 0.807 -10.62 0.01652 
726-Leu, 734-Val, 
751-Ala, 753-Lys, 
770-Glu, 774-Met, 
783-Ser, 785-Leu, 
796-Leu, 798-Thr, 
799-Gln, 800-Leu, 
801-Met, 850-Asn, 
852-Leu, 862-Thr, 
863-Asp 
1 
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Docking was performed using 
AutoDock 4.2.6 at the active site of 
HER2 receptor as used on validation 
process. A number of runs have been 
set on 100 genetic algorithms to improve 
the accuracy of docking results (Morris 
et al., 2009). For each test ligand, one 
pose with most negative ΔG and lowest 
Ki scores was selected as 
representatives of test ligands 
(Cosconati et al., 2010). The docking 
result data of five ligands to HER2 were 
compared each other as shown in Table 
3. 
Table 3. Docking results of berberine derivatives at HER2 receptor 
Parameters BBR-0 BBR-1 BBR-2 BBR-3 BBR-4 BBR-5 
ΔG 
(kcal/mol) 
-9.34 -9.54 -9.46 -9.47 -9.14 -9.70 
Ki, (µM) 0.14181 0.10243 0.11659 0.11400 0.20059 0.07757 
Amino acids 
residues 
726-Leu 
734-Val 
751-Ala 
753-Lys 
785-Leu 
796-Leu 
798-Thr 
805-Cys 
849-Arg 
- 
862-Thr 
863-Asp 
- 
726-Leu 
734-Val 
751-Ala 
753-Lys 
785-Leu 
796-Leu 
798-Thr 
- 
849-Arg 
- 
862-Thr 
863-Asp 
- 
726-Leu 
734-Val 
751-Ala 
753-Lys 
785-Leu 
796-Leu 
798-Thr 
- 
- 
- 
862-Thr 
863-Asp 
864-Phe 
726-Leu 
734-Val 
751-Ala 
753-Lys 
785-Leu 
796-Leu 
798-Thr 
- 
849-Arg 
852-Leu 
862-Thr 
863-Asp 
- 
726-Leu 
734-Val 
751-Ala 
753-Lys 
785-Leu 
796-Leu 
798-Thr 
- 
849-Arg 
- 
862-Thr 
863-Asp 
864-Phe 
726-Leu 
734-Val 
751-Ala 
753-Lys 
785-Leu 
796-Leu 
798-Thr 
805-Cys 
849-Arg 
- 
862-Thr 
863-Asp 
864-Phe 
Numbers of 
hydrogen 
bonds 
0 0 0 1 1 0 
 
All ligands provided a negative 
score of ΔG, indicated that interaction 
between HER2 receptor active site and 
all ligands will occur spontaneously 
(Kontoyianni et al., 2004). Compared to 
other ligands, berberine-4 had the less 
negative ΔG and highest Ki scores, 
indicating deletion of pharmacophore at 
position 23 (O-23 to C-23) was resulting 
in loss of affinity of berberine. In contrast 
to berberine-4, other ligands had more 
negative ΔG and lower Ki scores than 
berberine, indicating pharmacophore at 
that position was not preferable as 
HER2 inhibitor. Regarding docking 
results, another test ligand namely 
berberine-6 was sketched contain the 
only pharmacophore at position 23, as 
shown in Table 4. 
Table 4. 3D structure of berberine-6 
Compounds 2D structure 3D structure 
Berberine-6 
(BBR-6) 
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Another docking process then 
performed again using newly-designed 
berberine-6 toward HER2. Docking 
result then compared to TAK-285 as 
known HER2 inhibitor to analyze 
similarities and differences between 
docking results of two compounds as 
shown in Table 5. 
 
Table 5. Comparison of docking results between TAK-285 and BBR-6 
Parameters TAK-285 BBR-6 
ΔG (kcal/mol) -10.62 -10.80 
Ki, (µM) 0.01652 0.01207 
Amino acids residues 
726-Leu 
734-Val 
751-Ala 
753-Lys 
770-Glu 
774-Met 
783-Ser 
785-Leu 
796-Leu 
798-Thr 
799-Gln 
800-Leu 
801-Met 
850-Asn 
852-Leu 
862-Thr 
863-Asp 
- 
726-Leu 
734-Val 
751-Ala 
753-Lys 
- 
- 
- 
785-Leu 
796-Leu 
798-Thr 
- 
- 
- 
- 
852-Leu 
- 
863-Asp 
864-Phe 
Numbers of hydrogen bonds 1 0 
 
More observation conducted to 
reveal the interaction between 
berberine-6 and HER2 receptor active 
site by overlay the docking result of 
berberine-6 with the redocking result of 
TAK-285 as shown in Figure 3. 
Berberine-6 was docked into very similar 
position and orientation again TAK-285 
(Figure 3a), while the interactions 
between berberine-6 and amino acids 
residues of HER2 active site also occur 
tightly without any obstacle (Figure 3b). 
 
(a)     (b) 
Figure 3. Comparison between docking results of TAK-285 (red) and BBR-6 
(blue) (a); amino acids residues from docking results of BBR-6 toward HER-2 (b)
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Whether berberine-6 had the 
same activity with TAK-285 or not was 
still unclear. However, since comparison 
results indicated almost every amino 
acids residues which interacted with 
berberine-6 also interacted with TAK-
285 (9 out of 10), there was big 
possibility that berberine-6 also inhibits 
HER2 like TAK-285. Since HER2 
inhibition was a key primary target for 
HER2-positive breast cancer therapy, 
this study results indicated that 
berberine-6 had the potency to be 
developed as HER2 inhibitor. 
 
CONCLUSION 
This study was successfully 
described the most important 
pharmacophore of berberine as HER2 
inhibitor, which occurs at position 
number 23. Deletion of other 
pharmacophores resulting in an 
increase of berberine affinity towards 
HER2 active site with ΔG and Ki scores 
-10.80 kcal/mol and 12.07 nM, 
respectively. This result also opens up 
opportunities to further development of 
berberine as a potent HER2 inhibitor by 
optimizing the interactions mainly with 
another pharmacophore at position 
number 23. Thus, this study clearly 
indicates a promising potential of 
berberine derivatives to be developed as 
HER2 inhibitor for HER2-positive breast 
cancer therapy. 
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